EGFR and neuroblastoma: To investigate whether inhibition of EGFR signaling might have beneficial effect for neuroblastoma patients we treated IMR-32 neuroblastoma cells with increasing doses of EGFR inhibitors: lapatinib (0.1–10 μM) and gefitinib (0.5–15 μM) alone and in combination with 5 μg/mL of ch14.18/CHO therapeutic antibody for 72 h and performed ATP measurements (Figures 5C,D).